CL2022001178A1 - Ligandos de la pseudoquinasa tyk2 - Google Patents
Ligandos de la pseudoquinasa tyk2Info
- Publication number
- CL2022001178A1 CL2022001178A1 CL2022001178A CL2022001178A CL2022001178A1 CL 2022001178 A1 CL2022001178 A1 CL 2022001178A1 CL 2022001178 A CL2022001178 A CL 2022001178A CL 2022001178 A CL2022001178 A CL 2022001178A CL 2022001178 A1 CL2022001178 A1 CL 2022001178A1
- Authority
- CL
- Chile
- Prior art keywords
- ligands
- tyk2
- tyk2 pseudokinase
- pseudokinase ligands
- pseudokinase
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 3
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 abstract 2
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933179P | 2019-11-08 | 2019-11-08 | |
| US202063046514P | 2020-06-30 | 2020-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001178A1 true CL2022001178A1 (es) | 2023-02-03 |
Family
ID=75846491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001178A CL2022001178A1 (es) | 2019-11-08 | 2022-05-04 | Ligandos de la pseudoquinasa tyk2 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11753411B2 (enExample) |
| EP (1) | EP4054581B1 (enExample) |
| JP (1) | JP7635228B2 (enExample) |
| KR (1) | KR102938141B1 (enExample) |
| CN (1) | CN114929226B (enExample) |
| AU (1) | AU2020378345B2 (enExample) |
| BR (1) | BR112022008821A2 (enExample) |
| CA (1) | CA3160637A1 (enExample) |
| CL (1) | CL2022001178A1 (enExample) |
| CO (1) | CO2022007814A2 (enExample) |
| GE (1) | GEP20257840B (enExample) |
| IL (1) | IL292785B2 (enExample) |
| MX (1) | MX2022005563A (enExample) |
| PH (1) | PH12022551105A1 (enExample) |
| TW (1) | TWI882032B (enExample) |
| UA (1) | UA129894C2 (enExample) |
| WO (1) | WO2021092246A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66346B1 (sr) | 2018-10-22 | 2025-01-31 | Alumis Inc | Inhibitori tyk2 i njihova upotreba |
| SG11202108619SA (en) * | 2019-02-07 | 2021-09-29 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| US20220177486A1 (en) * | 2019-03-11 | 2022-06-09 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| SG11202110523XA (en) | 2019-03-26 | 2021-10-28 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| CN114929226B (zh) | 2019-11-08 | 2024-09-27 | 温缇克斯生物科学公司 | Tyk2假激酶配体 |
| US12486274B2 (en) | 2020-01-13 | 2025-12-02 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
| IL301385A (en) | 2020-09-16 | 2023-05-01 | Alumis Inc | TYK2 inhibitors and their use |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| JP2025522917A (ja) * | 2022-07-06 | 2025-07-17 | ベンティックス バイオサイエンシーズ，インク． | Ｔｙｋ２阻害剤の結晶形態 |
| CN120897919A (zh) * | 2023-01-13 | 2025-11-04 | 温缇克斯生物科学公司 | Tyk2抑制剂的制备 |
| CN117247389A (zh) * | 2023-09-18 | 2023-12-19 | 南京友怡医药科技有限公司 | 一种靶向药物化合物及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| JP4564485B2 (ja) | 2003-02-28 | 2010-10-20 | 帝人ファーマ株式会社 | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| US7538120B2 (en) * | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US20070082900A1 (en) * | 2005-10-06 | 2007-04-12 | Schering Corporation | Methods for inhibiting protein kinases |
| WO2010118207A1 (en) | 2009-04-09 | 2010-10-14 | Schering Corporation | Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors |
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| KR102477063B1 (ko) | 2016-10-28 | 2022-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물 |
| AU2018230737B2 (en) | 2017-03-08 | 2022-09-22 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors, uses, and methods for production thereof |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018213365A1 (en) | 2017-05-15 | 2018-11-22 | Dana-Farber Cancer Institute, Inc. | Compounds for treating dengue virus infection and other viral infections |
| IL317854A (en) * | 2017-07-28 | 2025-02-01 | Takeda Pharmaceuticals Co | TYK2 inhibitors and their uses |
| EP3849981B1 (en) | 2018-09-10 | 2023-02-01 | Eli Lilly and Company | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus |
| JP7619951B2 (ja) * | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| TWI800696B (zh) | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| SG11202108619SA (en) * | 2019-02-07 | 2021-09-29 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| US20220177486A1 (en) | 2019-03-11 | 2022-06-09 | Esker Therapeutics, Inc. | Tyk2 inhibitors and uses thereof |
| SG11202110523XA (en) * | 2019-03-26 | 2021-10-28 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| CN114929226B (zh) | 2019-11-08 | 2024-09-27 | 温缇克斯生物科学公司 | Tyk2假激酶配体 |
-
2020
- 2020-11-05 CN CN202080092581.XA patent/CN114929226B/zh active Active
- 2020-11-05 KR KR1020227018394A patent/KR102938141B1/ko active Active
- 2020-11-05 TW TW109138709A patent/TWI882032B/zh active
- 2020-11-05 EP EP20884019.9A patent/EP4054581B1/en active Active
- 2020-11-05 MX MX2022005563A patent/MX2022005563A/es unknown
- 2020-11-05 IL IL292785A patent/IL292785B2/en unknown
- 2020-11-05 CA CA3160637A patent/CA3160637A1/en active Pending
- 2020-11-05 GE GEAP202015969A patent/GEP20257840B/en unknown
- 2020-11-05 US US17/090,805 patent/US11753411B2/en active Active
- 2020-11-05 BR BR112022008821A patent/BR112022008821A2/pt unknown
- 2020-11-05 WO PCT/US2020/059210 patent/WO2021092246A1/en not_active Ceased
- 2020-11-05 JP JP2022525957A patent/JP7635228B2/ja active Active
- 2020-11-05 PH PH1/2022/551105A patent/PH12022551105A1/en unknown
- 2020-11-05 AU AU2020378345A patent/AU2020378345B2/en active Active
- 2020-11-05 UA UAA202201178A patent/UA129894C2/uk unknown
-
2022
- 2022-05-04 CL CL2022001178A patent/CL2022001178A1/es unknown
- 2022-06-01 CO CONC2022/0007814A patent/CO2022007814A2/es unknown
-
2023
- 2023-07-06 US US18/348,296 patent/US20230348478A1/en not_active Abandoned
-
2026
- 2026-02-12 US US19/538,596 patent/US20260176281A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4054581A1 (en) | 2022-09-14 |
| KR102938141B1 (ko) | 2026-03-11 |
| UA129894C2 (uk) | 2025-09-03 |
| IL292785A (en) | 2022-07-01 |
| CO2022007814A2 (es) | 2022-09-09 |
| CA3160637A1 (en) | 2021-05-14 |
| US20210139486A1 (en) | 2021-05-13 |
| IL292785B2 (en) | 2025-09-01 |
| AU2020378345B2 (en) | 2026-06-25 |
| IL292785B1 (en) | 2025-05-01 |
| TW202128698A (zh) | 2021-08-01 |
| CN114929226B (zh) | 2024-09-27 |
| KR20220107194A (ko) | 2022-08-02 |
| CN114929226A (zh) | 2022-08-19 |
| TWI882032B (zh) | 2025-05-01 |
| EP4054581A4 (en) | 2023-11-22 |
| US11753411B2 (en) | 2023-09-12 |
| US20260176281A1 (en) | 2026-06-25 |
| JP7635228B2 (ja) | 2025-02-25 |
| AU2020378345A1 (en) | 2022-06-02 |
| BR112022008821A2 (pt) | 2022-08-23 |
| WO2021092246A1 (en) | 2021-05-14 |
| EP4054581B1 (en) | 2026-07-22 |
| GEP20257840B (en) | 2025-12-25 |
| US20230348478A1 (en) | 2023-11-02 |
| PH12022551105A1 (en) | 2023-11-20 |
| MX2022005563A (es) | 2022-08-19 |
| JP2022553841A (ja) | 2022-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022007814A2 (es) | Ligandos de la pseudoquinasa tyk2 | |
| MX2021009555A (es) | Ligandos de pseudocinasa tyk2. | |
| MX2021011723A (es) | Ligandos de pseudocinasa tyk2. | |
| MX2020013853A (es) | Compuestos innovadores. | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| MX2017011269A (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| MX390120B (es) | Moduladores de la somatostatina y usos de los mismos. | |
| EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
| MX2019010949A (es) | Moduladores de somatostatina y usos de los mismos. | |
| MX2022000712A (es) | Moduladores de nlrp3. | |
| MX2021002916A (es) | Pirfenidona enriquecida con deuterio y métodos para su uso. | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| MX2018011785A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue. | |
| MX2021008941A (es) | Moduladores gpr35. | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| MX2021013602A (es) | Inhibidores de jak. | |
| MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| EA201891680A1 (ru) | Производные индана в качестве модуляторов mglur7 | |
| MX2022001702A (es) | Inhibidores de jak. |